Paper Details

  1. Home
  2. Paper Details

Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies.

Author: , BayerAndreas, OeverhausUlrich, SkrotzkiFrank-Eugen, StewartWilliam C, WeilerWinfried

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Latanoprost effectively reduced intraocular pressure (IOP) in patients with glaucoma, with a low rate of side effects and discontinuations.
Paper Details　
Original Abstract of the Article :
AIM: The aim of this study was to evaluate the long-term follow-up of patients who were changed to latanoprost from previous glaucoma therapies. METHODS: Primary open-angle, exfoliative or chronic angle-closure glaucoma, or ocular hypertensive patients who switched to latanoprost therapy with a 2-y...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/jop.2004.20.470

データ提供：米国国立医学図書館（NLM）

The Long-Term Efficacy of Latanoprost for Glaucoma

Glaucoma is a serious eye condition that can lead to blindness if left untreated. This study evaluated the long-term efficacy and safety of latanoprost 0.005% monotherapy in patients who switched from previous glaucoma therapies. The researchers followed 1,571 patients for two years and found that latanoprost consistently reduced intraocular pressure (IOP) across all treatment groups, demonstrating its effectiveness in managing glaucoma.

Latanoprost Shows Sustained Benefit in Glaucoma Management

The two-year follow-up results showed a significant and sustained reduction in IOP in patients who switched to latanoprost monotherapy. This suggests that latanoprost is a safe and effective long-term treatment option for glaucoma.

Maintaining Clear Vision with Latanoprost

Glaucoma can be a daunting diagnosis, but this study suggests that latanoprost can provide a stable solution for managing IOP over time. This means that patients can maintain their vision and avoid further complications by consistently using this medication. It's like a steady camel caravan navigating the desert, ensuring a safe and clear path for the future.

Dr.Camel's Conclusion

This study reinforces the importance of ongoing research in glaucoma management, highlighting the effectiveness and safety of latanoprost as a long-term treatment option. While individual responses may vary, the consistent reduction in IOP over two years suggests that latanoprost can be a reliable and effective treatment for many individuals with glaucoma.
Date :
  1. Date Completed 2006-06-19
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

15684807

DOI: Digital Object Identifier

10.1089/jop.2004.20.470

Related Literature

Article Analysis
・Side Effects of metipranolol ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.